All In Biotech

Drug Trial Radar · NCT00043303

Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis

A Multicenter Study of the Safety and Anti-Fibrotic Efficacy of Interferon-Gamma 1b (Actimmune) in Patients With Severe Lever Fibrosis or Compensated Cirrhosis Due to Hepatitis C.

Last checked: Nov 20, 2026Latest source record: Nov 1, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 502 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

502

Actual

Start

Sep 2001

Primary completion

Not stated

Study completion Nov 2003

Sponsor

Lead sponsor
InterMuneIndustry
Sponsor type
Industry
First posted
Aug 9, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to test the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) injected subcutaneously (under the skin) for the treatment of advanced liver fibrosis and cirrhosis in patients with chronic hepatitis C infections. IFN-g 1b is not currently approved for the treatment of liver fibrosis.

Conditions

  • Liver Fibrosis
  • Cirrhosis

Interventions

  • interferon gamma-1bDrug

    100 or 200 mcg, SQ, 3x per week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ishak fibrosis scoreTime frame: 52 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.